Cargando…

PD-1 blockade upregulate TIM-3 expression as a compensatory regulation of immune check point receptors in HNSCC TIL

Detalles Bibliográficos
Autores principales:	Shayan, Gulidanna, Ferris, Robert L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649333/ http://dx.doi.org/10.1186/2051-1426-3-S2-P196

Ejemplares similares

Differential expression of PD-1 and Tim-3 marks activation versus exhaustion status of T cells in the tumor microenvironment
por: Li, Jing, et al.
Publicado: (2014)

Level of PD-1 expression on CD8+ T cells influence prognosis and respond to PD-1 therapy in a murine model
por: Kansy, Benjamin A, et al.
Publicado: (2015)

IFNγ-induced PD-L1 expression is JAK2 but not JAK1 dependent and its inhibition enhances NK-cetuximab mediated ADCC of HNSCC cells
por: Concha-Benavente, Fernando, et al.
Publicado: (2014)

Image guided cryoablation of cancer with intra-tumoral injection of anti-CTLA-4 and PD-1 immune check-point inhibitors
por: Rosenberg, Mark A, et al.
Publicado: (2015)

Genetic inference of immune responsiveness of melanoma cancer patients to TIL therapy
por: Sommariva, Michele, et al.
Publicado: (2013)

TIM-3(+) T cells are not exhausted but activated cells in the tumor microenvironment
por: Jie, Hyun-Bae, et al.
Publicado: (2013)

Fewer tumour-specific PD-1(+)CD8(+) TILs in high-risk “Infiltrating” HPV(−) HNSCC
por: Xu, Ke, et al.
Publicado: (2020)

Adoptive TIL in HPV-negative oral scca
por: Leidner, Rom, et al.
Publicado: (2015)

IL-12 stimuli during ex vivo expansion not only prevents the upregulation of PD1 on tumor infiltrating adoptively transferred T cells but also on endogenous TILs which results in effective tumor regression
por: Diaz-Montero, C Marcela, et al.
Publicado: (2014)

Predictive immune biomarker signatures in the tumor microenvironment of melanoma metastases associated with tumor-infiltrating lymphocyte (TIL) therapy
por: Chen, Jieqing, et al.
Publicado: (2014)

Clinical scale zinc finger nuclease (ZFN)-driven gene-editing of PD-1 in tumor infiltrating lymphocytes (TIL) for the potential treatment of metastatic melanoma
por: Beane, Joal D, et al.
Publicado: (2014)

Preclinical to clinical translation of anti-PD-1 blockade
por: Hirsch, Heather, et al.
Publicado: (2015)

Rapid expansion of TILs from patients with glioma and recognition of autologous tumor
por: Zhenjiang, Liu, et al.
Publicado: (2014)

PD-1(T) TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC
por: Hummelink, Karlijn, et al.
Publicado: (2022)

Targeting STAT3 Abrogates Tim-3 Upregulation of Adaptive Resistance to PD-1 Blockade on Regulatory T Cells of Melanoma
por: Huang, Lili, et al.
Publicado: (2021)

Antigen-specific TIL therapy for melanoma: a flexible platform for personalized cancer immunotherapy
por: Kelderman, Sander, et al.
Publicado: (2013)

Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade
por: Tian, Tian, et al.
Publicado: (2021)

TIL classified to memory state are correlated with response to immune checkpoint blockade
por: Jedema, Inge, et al.
Publicado: (2022)

Modification of BTLA signaling motifs in TIL exhibits positive signals that mediate anti-tumor control
por: Ritthipichai, Krit, et al.
Publicado: (2015)

An evaluation of autologous tumor-reactive TIL generation from head and neck squamous cell cancers
por: Mougdil, Tarsem, et al.
Publicado: (2015)

Enhanced tumor-infiltrating lymphocytes (eTIL) for cellular therapy of patients with pancreatic cancer or glioblastoma
por: Meng, Qingda, et al.
Publicado: (2015)

Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4(+) T Cells
por: Saleh, Reem, et al.
Publicado: (2019)

Radiotherapy induces responsiveness of a resistant mammary carcinoma to PD-1 blockade
por: Diamond, Julie, et al.
Publicado: (2014)

Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC
por: Lin, Weimin, et al.
Publicado: (2018)

Sequential tumor and dual immune targeted immunotherapy: anti-lymphoma activity of Rituximab with 4-1bb stimulation and PD-1 blockade
por: Mueller, Antonia MS, et al.
Publicado: (2014)

Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors
por: Ayers, Mark, et al.
Publicado: (2015)

MAP kinase inhibitors stimulate T cell and anti-tumor activity in combination with blockade of the PD-L1/PD-1 interaction
por: Irving, Bryan A, et al.
Publicado: (2013)

Identification of predictive biomarker signatures in melanoma tumors associated with response to tumor-infiltrating lymphocyte (TIL) therapy
por: Chen, Jie Qing, et al.
Publicado: (2013)

The extent of metalloproteinase-mediated LAG3 cleavage limits the efficacy of PD1 blockade
por: Andrews, Lawrence P, et al.
Publicado: (2015)

Tim-3 signaling blockade with α-lactose induces compensatory TIGIT expression in Plasmodium berghei ANKA-infected mice
por: Zhang, Yiwei, et al.
Publicado: (2019)

Genetically engineered lymphocytes in metastatic melanoma: TIL 1383I TCR transduced T-cells are detectable after infusion
por: Regan, Courtney, et al.
Publicado: (2013)

Epitope optimization of a DNA vaccine targeting SSX-2 leads to PD-1 upregulation on antigen-specific CD8 T cells and PD-L1 upregulation on tumor cells
por: Rekoske, Brian, et al.
Publicado: (2013)

Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models
por: Spahn, Jessica, et al.
Publicado: (2015)

Innate resistance of PD-1 blockade through loss of function mutations in JAK resulting in inability to express PD-L1 upon interferon exposure
por: Shin, Daniel, et al.
Publicado: (2015)

Data entry checking - is it necessary?
por: McPherson, Gladys
Publicado: (2013)

Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
por: Huang, Ruea-Yea, et al.
Publicado: (2016)

PD-1 blockade reverses viral infection-induced loss of anti-tumor CD8+ T cell responses
por: Huelsmann, Erica, et al.
Publicado: (2013)

Variable density of CD8+ and CD25+ programmed cell death-1 (PD-1) ligand (PD-L1) CD4+ T cells within the tumor microenvironment causes differential responses to the PD-1/PD-L1 blockade
por: Wu, Si-Pei, et al.
Publicado: (2015)

Expression of immune check point gene TIM-3 in patients newly diagnosed with acute myeloid leukemia: Significance and impact on outcome
por: Kamal, Amany M., et al.
Publicado: (2021)

Enhanced anti-tumor effects of the PD-1/PD-L1 blockade by combining a highly absorptive form of NF-kB/STAT3 inhibitor curcumin
por: Hayakawa, Taeko, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_rbi2j6kqfubg229s3tp08v6vu5